Search

Your search keyword '"Riddell, Amy"' showing total 34 results
Start Over Author "Riddell, Amy"
34 results on '"Riddell, Amy"'

1. Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries

Author

Kakaraskoska Boceska, Biljana, Vilken, Tuba, Xavier, Basil Britto, Kostyanev, Tomislav, Lin, Qiang, Lammens, Christine, Ellis, Sally, O’Brien, Seamus, da Costa, Renata Maria Augusto, Cook, Aislinn, Russell, Neal, Bielicki, Julia, Riddell, Amy, Stohr, Wolfgang, Walker, Ann Sarah, Berezin, Eitan Naaman, Roilides, Emmanuel, De Luca, Maia, Romani, Lorenza, Ballot, Daynia, Dramowski, Angela, Wadula, Jeannette, Lochindarat, Sorasak, Boonkasidecha, Suppawat, Namiiro, Flavia, Ngoc, Hoang Thi Bich, Tran, Minh Dien, Cressey, Tim R., Preedisripipat, Kanchana, Berkley, James A., Musyimi, Robert, Zarras, Charalampos, Nana, Trusha, Whitelaw, Andrew, da Silva, Cely Barreto, Jaglal, Prenika, Ssengooba, Willy, Saha, Samir K., Islam, Mohammad Shahidul, Mussi-Pinhata, Marisa Marcia, Carvalheiro, Cristina Gardonyi, Piddock, Laura J. V., Heath, Paul T., Malhotra-Kumar, Surbhi, Sharland, Michael, Glupczynski, Youri, and Goossens, Herman

Published
2024
Full Text
View/download PDF

4. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

Author

Murray, Christopher J L, Ikuta, Kevin Shunji, Sharara, Fablina, Swetschinski, Lucien, Robles Aguilar, Gisela, Gray, Authia, Han, Chieh, Bisignano, Catherine, Rao, Puja, Wool, Eve, Johnson, Sarah C, Browne, Annie J, Chipeta, Michael Give, Fell, Frederick, Hackett, Sean, Haines-Woodhouse, Georgina, Kashef Hamadani, Bahar H, Kumaran, Emmanuelle A P, McManigal, Barney, Achalapong, Sureeruk, Agarwal, Ramesh, Akech, Samuel, Albertson, Samuel, Amuasi, John, Andrews, Jason, Aravkin, Aleskandr, Ashley, Elizabeth, Babin, François-Xavier, Bailey, Freddie, Baker, Stephen, Basnyat, Buddha, Bekker, Adrie, Bender, Rose, Berkley, James A, Bethou, Adhisivam, Bielicki, Julia, Boonkasidecha, Suppawat, Bukosia, James, Carvalheiro, Cristina, Castañeda-Orjuela, Carlos, Chansamouth, Vilada, Chaurasia, Suman, Chiurchiù, Sara, Chowdhury, Fazle, Clotaire Donatien, Rafai, Cook, Aislinn J, Cooper, Ben, Cressey, Tim R, Criollo-Mora, Elia, Cunningham, Matthew, Darboe, Saffiatou, Day, Nicholas P J, De Luca, Maia, Dokova, Klara, Dramowski, Angela, Dunachie, Susanna J, Duong Bich, Thuy, Eckmanns, Tim, Eibach, Daniel, Emami, Amir, Feasey, Nicholas, Fisher-Pearson, Natasha, Forrest, Karen, Garcia, Coralith, Garrett, Denise, Gastmeier, Petra, Giref, Ababi Zergaw, Greer, Rachel Claire, Gupta, Vikas, Haller, Sebastian, Haselbeck, Andrea, Hay, Simon I, Holm, Marianne, Hopkins, Susan, Hsia, Yingfen, Iregbu, Kenneth C, Jacobs, Jan, Jarovsky, Daniel, Javanmardi, Fatemeh, Jenney, Adam W J, Khorana, Meera, Khusuwan, Suwimon, Kissoon, Niranjan, Kobeissi, Elsa, Kostyanev, Tomislav, Krapp, Fiorella, Krumkamp, Ralf, Kumar, Ajay, Kyu, Hmwe Hmwe, Lim, Cherry, Lim, Kruy, Limmathurotsakul, Direk, Loftus, Michael James, Lunn, Miles, Ma, Jianing, Manoharan, Anand, Marks, Florian, May, Jürgen, Mayxay, Mayfong, Mturi, Neema, Munera-Huertas, Tatiana, Musicha, Patrick, Musila, Lilian A, Mussi-Pinhata, Marisa Marcia, Naidu, Ravi Narayan, Nakamura, Tomoka, Nanavati, Ruchi, Nangia, Sushma, Newton, Paul, Ngoun, Chanpheaktra, Novotney, Amanda, Nwakanma, Davis, Obiero, Christina W, Ochoa, Theresa J, Olivas-Martinez, Antonio, Olliaro, Piero, Ooko, Ednah, Ortiz-Brizuela, Edgar, Ounchanum, Pradthana, Pak, Gideok D, Paredes, Jose Luis, Peleg, Anton Yariv, Perrone, Carlo, Phe, Thong, Phommasone, Koukeo, Plakkal, Nishad, Ponce-de-Leon, Alfredo, Raad, Mathieu, Ramdin, Tanusha, Rattanavong, Sayaphet, Riddell, Amy, Roberts, Tamalee, Robotham, Julie Victoria, Roca, Anna, Rosenthal, Victor Daniel, Rudd, Kristina E, Russell, Neal, Sader, Helio S, Saengchan, Weerawut, Schnall, Jesse, Scott, John Anthony Gerard, Seekaew, Samroeng, Sharland, Mike, Shivamallappa, Madhusudhan, Sifuentes-Osornio, Jose, Simpson, Andrew J, Steenkeste, Nicolas, Stewardson, Andrew James, Stoeva, Temenuga, Tasak, Nidanuch, Thaiprakong, Areerat, Thwaites, Guy, Tigoi, Caroline, Turner, Claudia, Turner, Paul, van Doorn, H Rogier, Velaphi, Sithembiso, Vongpradith, Avina, Vongsouvath, Manivanh, Vu, Huong, Walsh, Timothy, Walson, Judd L, Waner, Seymour, Wangrangsimakul, Tri, Wannapinij, Prapass, Wozniak, Teresa, Young Sharma, Tracey E M W, Yu, Kalvin C, Zheng, Peng, Sartorius, Benn, Lopez, Alan D, Stergachis, Andy, Moore, Catrin, Dolecek, Christiane, and Naghavi, Mohsen

Published
2022
Full Text
View/download PDF

5. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)

Author

Russell, Neal J., Stöhr, Wolfgang, Plakkal, Nishad, Cook, Aislinn, Berkley, James A., Adhisivam, Bethou, Agarwal, Ramesh, Ahmed, Nawshad Uddin, Balasegaram, Manica, Ballot, Daynia, Bekker, Adrie, Berezin, Eitan Naaman, Bilardi, Davide, Boonkasidecha, Suppawat, Carvalheiro, Cristina G., Chami, Neema, Chaurasia, Suman, Chiurchiu, Sara, Colas, Viviane Rinaldi Favarin, Cousens, Simon, Cressey, Tim R., de Assis, Ana Carolina Dantas, Dien, Tran Minh, Ding, Yijun, Dung, Nguyen Trong, Dong, Han, Dramowski, Angela, DS, Madhusudhan, Dudeja, Ajay, Feng, Jinxing, Glupczynski, Youri, Goel, Srishti, Goossens, Herman, Hao, Doan Thi Huong, Khan, Mahmudul Islam, Huertas, Tatiana Munera, Islam, Mohammad Shahidul, Jarovsky, Daniel, Khavessian, Nathalie, Khorana, Meera, Kontou, Angeliki, Kostyanev, Tomislav, Laoyookhon, Premsak, Lochindarat, Sorasak, Larsson, Mattias, Luca, Maia De, Malhotra-Kumar, Surbhi, Mondal, Nivedita, Mundhra, Nitu, Musoke, Philippa, Mussi-Pinhata, Marisa M., Nanavati, Ruchi, Nakwa, Firdose, Nangia, Sushma, Nankunda, Jolly, Nardone, Alessandra, Nyaoke, Borna, Obiero, Christina W., Owor, Maxensia, Ping, Wang, Preedisripipat, Kanchana, Qazi, Shamim, Qi, Lifeng, Ramdin, Tanusha, Riddell, Amy, Romani, Lorenza, Roysuwan, Praewpan, Saggers, Robin, Roilides, Emmanuel, Saha, Samir K., Sarafidis, Kosmas, Tusubira, Valerie, Thomas, Reenu, Velaphi, Sithembiso, Vilken, Tuba, Wang, Xiaojiao, Wang, Yajuan, Yang, Yonghong, Zunjie, Liu, Ellis, Sally, Bielicki, Julia A., Walker, A. Sarah, Heath, Paul T., and Sharland, Mike

Subjects
Infants -- Patient outcomes, Sepsis -- Diagnosis -- Care and treatment, Antibiotics -- Dosage and administration, Hospital patients -- Care and treatment, Market trend/market analysis, Biological sciences
Abstract

Background There is limited data on antibiotic treatment in hospitalized neonates in low- and middle-income countries (LMICs). We aimed to describe patterns of antibiotic use, pathogens, and clinical outcomes, and to develop a severity score predicting mortality in neonatal sepsis to inform future clinical trial design. Methods and findings Hospitalized infants A total of 3,204 infants were enrolled, with median birth weight of 2,500 g (IQR 1,400 to 3,000) and postnatal age of 5 days (IQR 1 to 15). 206 different empiric antibiotic combinations were started in 3,141 infants, which were structured into 5 groups based on the World Health Organization (WHO) AWaRe classification. Approximately 25.9% (n = 814) of infants started WHO first line regimens (Group 1-Access) and 13.8% (n = 432) started WHO second-line cephalosporins (cefotaxime/ceftriaxone) (Group 2-'Low' Watch). The largest group (34.0%, n = 1,068) started a regimen providing partial extended-spectrum beta-lactamase (ESBL)/pseudomonal coverage (piperacillin-tazobactam, ceftazidime, or fluoroquinolone-based) (Group 3-'Medium' Watch), 18.0% (n = 566) started a carbapenem (Group 4-'High' Watch), and 1.8% (n = 57) a Reserve antibiotic (Group 5, largely colistin-based), and 728/2,880 (25.3%) of initial regimens in Groups 1 to 4 were escalated, mainly to carbapenems, usually for clinical deterioration (n = 480; 65.9%). A total of 564/3,195 infants (17.7%) were blood culture pathogen positive, of whom 62.9% (n = 355) had a gram-negative organism, predominantly Klebsiella pneumoniae (n = 132) or Acinetobacter spp. (n = 72). Both were commonly resistant to WHO-recommended regimens and to carbapenems in 43 (32.6%) and 50 (71.4%) of cases, respectively. MRSA accounted for 33 (61.1%) of 54 Staphylococcus aureus isolates. Overall, 350/3,204 infants died (11.3%; 95% CI 10.2% to 12.5%), 17.7% if blood cultures were positive for pathogens (95% CI 14.7% to 21.1%, n = 99/564). A baseline NeoSep Severity Score had a C-index of 0.76 (0.69 to 0.82) in the validation sample, with mortality of 1.6% (3/189; 95% CI: 0.5% to 4.6%), 11.0% (27/245; 7.7% to 15.6%), and 27.3% (12/44; 16.3% to 41.8%) in low (score 0 to 4), medium (5 to 8), and high (9 to 16) risk groups, respectively, with similar performance across subgroups. A related NeoSep Recovery Score had an area under the receiver operating curve for predicting death the next day between 0.8 and 0.9 over the first week. There was significant variation in outcomes between sites and external validation would strengthen score applicability. Conclusion Antibiotic regimens used in neonatal sepsis commonly diverge from WHO guidelines, and trials of novel empiric regimens are urgently needed in the context of increasing antimicrobial resistance (AMR). The baseline NeoSep Severity Score identifies high mortality risk criteria for trial entry, while the NeoSep Recovery Score can help guide decisions on regimen change. NeoOBS data informed the NeoSep1 antibiotic trial (ISRCTN48721236), which aims to identify novel first- and second-line empiric antibiotic regimens for neonatal sepsis. Trial registration ClinicalTrials.gov, (NCT03721302)., Author(s): Neal J. Russell 1,*, Wolfgang Stöhr 2, Nishad Plakkal 3, Aislinn Cook 1, James A. Berkley 4,5,6, Bethou Adhisivam 3, Ramesh Agarwal 7, Nawshad Uddin Ahmed 8, Manica Balasegaram [...]

Published
2023
Full Text
View/download PDF

7. The muscle-bone in children and adolescents with and without cystic fibrosis

Author

Riddell, Amy and Ward, Kate

Subjects
618.92, Bone, Muscle, cystic fibrosis, children, adolescents, growth, muscle-bone unit, imagining, pQCT, HR-pQCT, DXA
Abstract

Introduction: Puberty is a crucial period for rapid changes in bone mineral, size, geometry, and microarchitecture. The mechanostat theory postulates that increased mechanical loading will affect bone phenotype and strength during development and in later life. Individuals with cystic fibrosis (CF) have an increased risk of developing osteoporosis and fragility fractures in young adulthood, which may be caused by poor growth. The aim was to investigate whether sex and disease status modified the relationship between: 1) puberty and bone, and 2) muscle and bone. This would contribute to the understanding of how sex (males vs. females) and disease group (CF vs.controls) alters the relationship between bone and muscle in children and adolescents as they transition through puberty and who, on a population level, differ in the prevalence of osteoporosis and risk of fracture in later life. Methods and Analyses: This observational study used novel imaging and muscle assessment techniques to measure bone and muscle parameters in White Caucasian children and adolescents, aged 8 to 16 years, living in the UK, with children with CF (n=65) and controls (n=151). Anthropometry and pubertal status were assessed. Dual energy X-ray absorptiometry, peripheral quantitative computed tomography (pQCT), high-resolution pQCT, and jumping mechanography were used to measure bone and muscle outcomes. ANCOVA with Scheffé post hoc and multiple linear regression tests were performed. Data were adjusted according to the research aims and included covariates; sex, disease group, pubertal stage, age, quadratic age, height, weight, maximum force (Fmax), and maximum power (Pmax). Data are presented as beta-coefficient (%) and p-value, with the significance level set to p < 0.05. Results: In height adjusted analyses, among healthy participants, females had smaller bones and lower bone density compared to males. With pubertal maturation, females had lower apparent gains in the distal and proximal total area (Tt.Ar and CSA), distal cortical porosity (Ct.Po) and proximal bone strength (SSI) but higher apparent gains in distal and proximal cortical bone density(Ct.BMD, Ct.TMD, vBMD). Females had consistently lower distal total area (total CSA) and density (total vBMD), distal trabecular density(BV/TV) and number(Tb.N), and proximal cortical area(CSA) compared to males, across all stages of puberty. With increasing muscle force (Fmax), females had higher apparent gains in total body less head bone mineral (TBLH BMC) and bone area(BA), distal total and trabecular density (total and trab vBMD) compared to males. In contrast, with increasing muscle power (Pmax), females had higher apparent gains in distal total and cortical densities (D100, Ct.BMD and Ct.TMD), and distal trabecular thickness (Tb.Th), and proximal cortical density (cortical vBMD) but lower apparent gains in distal cortical porosity (Ct.Po) and trabecular number (Tb.N) compared to males. In height adjusted analyses, participants with CF had smaller bones and lower bone density compared to controls. With increasing pubertal maturation, participants with CF had lower apparent gains in total body less head bone mineral and bone area, and in distal trabecular density, cortical porosity, and trabecular thickness compared to controls. Participants with CF had consistently lower distal total and cortical area, distal total and trabecular densities and proximal bone strength compared to controls, across all stages of puberty. With increasing muscle force, participants with CF had lower apparent gains in total body less head bone mineral and bone area, distal total density, trabecular density, and trabecular number. In contrast, with increasing muscle power (Pmax), participants with CF had higher apparent gains in distal trabecular density (BV/TV) and trabecular number (Tb.N) compared to controls. Conclusion: These findings suggests that sex and disease status do modify the relationships between puberty and bone, and between muscle function and bone. Skeletal adaptation to muscle differs between sexes and in populations with chronic disease, which may explain sex and disease group differences in risks of osteoporosis and fracture. Bone adaptation to muscle in children with CF is altered, which may lead to narrow, under-mineralised bones, with lower bone strength in later life. Understanding better impairments in muscle functions may provide targets for intervention to improve skeletal health in later life.

Published
2016
Full Text
View/download PDF

9. Challenges in the Implementation of the NeoOBS Study, a Global Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of Neonatal Sepsis in the Hospital Setting

Author

Riddell, Amy, primary, Cook, Aislinn, additional, Khavessian, Nathalie, additional, Ellis, Sally, additional, Bilardi, Davide, additional, Correia, Erika, additional, Kostyanev, Tomislav, additional, Nardone, Alessandra, additional, Russell, Neal, additional, Vilken, Tuba, additional, Stohr, Wolfgang, additional, Adhisivam, Bethou, additional, Moraes, Iana Rosa Alves de, additional, Ahmed, Nawshad Uddin, additional, Bekker, Adrie, additional, Berezin, Eitan Naaman, additional, Boonkasidecha, Suppawat, additional, Carvalheiro, Cristina G., additional, Chauhan, Prachi, additional, Chiurchiù, Sara, additional, Chorafa, Elisavet, additional, Dramowski, Angela, additional, DS, Madhusudhan, additional, Feng, Jinxing, additional, Jia, Shengnan, additional, Kong, Yuan, additional, Kyohere, Mary, additional, Kontou, Angeliki, additional, Lochindarat, Sorasak, additional, De Luca, Maia, additional, Mphaphuli, Aripfani, additional, Mussi-Pinhata, Marisa M., additional, Murunga, Sheila, additional, Nakwa, Firdose Lambey, additional, Nangia, Sushma, additional, Nassolo, Erinah, additional, Hoang, Ngoc Thi Bin, additional, Obiero, Christina W., additional, Olson, Linus, additional, Ping, Wang, additional, Plakkal, Nishad, additional, Prasad, Priyanka, additional, Preedisripipat, Kanchana, additional, Rahman, Sheikh Wasik, additional, Seef, Tiffany, additional, Sukrakanchana, Pra-ornsuda, additional, Thomas, Reenu, additional, Yu, Zhang, additional, Zhang, Qiaoru, additional, Walker, A. Sarah, additional, Bielicki, Julia, additional, Heath, Paul T., additional, Sharland, Michael, additional, and Munera-Huertas, Tatiana, additional

Published
2023
Full Text
View/download PDF

10. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

Author

Bhatnagar, A, Burton, B, Chakravarthy, U, Eleftheriadis, H, Empeslidis, T, Gale, R, George, S, Habib, M, Kelly, S, Lotery, A, McKibbin, M, Membrey, L, Menon, G, Mushtaq, B, Nicholson, L, Ramu, J, Osoba, O, Patel, J, Prakash, P, Purbrick, R, Ross, A, Stylianides, A, Talks, J, Harding, S, Peto, T, Yeo, S T, Laidlaw, Alistair, Amoaku, Winfried, Hood, Gillian, Hitman, Graham A, Preece, Daniel, Burns, Paul, Walker, Sarah, Mensah, Evelyn, Karia, Niral, Sivaprasad, Sobha, Prevost, A Toby, Vasconcelos, Joana C, Riddell, Amy, Murphy, Caroline, Kelly, Joanna, Bainbridge, James, Tudor-Edwards, Rhiannon, Hopkins, David, and Hykin, Philip

Published
2017
Full Text
View/download PDF

12. Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS study

Author

Cook, Aislinn, primary, Ferreras-Antolin, Laura, additional, Adhisivam, Bethou, additional, Ballot, Daynia, additional, Berkley, James A, additional, Bernaschi, Paola, additional, Carvalheiro, Cristina G, additional, Chaikittisuk, Napaporn, additional, Chen, Yunsheng, additional, Chibabhai, Vindana, additional, Chitkara, Shweta, additional, Chiurchiu, Sara, additional, Chorafa, Elisavet, additional, Dien, Tran Minh, additional, Dramowski, Angela, additional, de Matos, Samantha Faria, additional, Feng, Jinxing, additional, Jarovsky, Daniel, additional, Kaur, Ravinder, additional, Khamjakkaew, Warunee, additional, Laoyookhong, Premsak, additional, Machanja, Edwin, additional, Mussi-Pinhata, Marisa M, additional, Namiiro, Flavia, additional, Natraj, Gita, additional, Naziat, Hakka, additional, Ngoc, Hoang Thi Bich, additional, Ondongo-Ezhet, Claude, additional, Preedisripipat, Kanchana, additional, Rahman, Hafizur, additional, Riddell, Amy, additional, Roilides, Emmanuel, additional, Russell, Neal, additional, Sastry, Apurba S, additional, Tasimwa, Hannington Baluku, additional, Tongzhen, Ji, additional, Wadula, Jeannette, additional, Wang, Yajuan, additional, Whitelaw, Andrew, additional, Wu, Dan, additional, Yadav, Varsha, additional, Yang, Gao, additional, Stohr, Wolfgang, additional, Bielicki, Julia Anna, additional, Ellis, Sally, additional, Warris, Adilia, additional, Heath, Paul T, additional, and Sharland, Michael, additional

Published
2023
Full Text
View/download PDF

13. The NeoSep Severity and Recovery scores to predict mortality in hospitalized neonates and young infants with sepsis derived from the global NeoOBS observational cohort study

Author

Russell, Neal, primary, Stöhr, Wolfgang, additional, Cook, Aislinn, additional, Berkley, James A, additional, Adhisivam, Bethou, additional, Agarwal, Ramesh, additional, Ahmed, Nawshad Uddin, additional, Balasegaram, Manica, additional, Chami, Neema, additional, Bekker, Adrie, additional, Bilardi, Davide, additional, Carvalheiro, Cristina G., additional, Chaurasia, Suman, additional, Favarin Colas, Viviane Rinaldi, additional, Cousens, Simon, additional, Dantas de Assis, Ana Carolina, additional, Dong, Han, additional, Dramowski, Angela, additional, Dung, Nguyen Trong, additional, Feng, Jinxing, additional, Glupczynski, Youri, additional, Goel, Srishti, additional, Goossens, Herman, additional, Huong Hao, Doan Thi, additional, Hasan, Mahmudul, additional, Huertas, Tatiana Munera, additional, Khavessian, Nathalie, additional, Kontou, Angeliki, additional, Kostyanev, Tomislav, additional, Laoyookhon, Premsak, additional, Lochindarat, Sorasak, additional, De Luca, Maia, additional, Malhotra-Kumar, Surbhi, additional, Mondal, Nivedita, additional, Mundhra, Nitu, additional, Musoke, Philippa, additional, Mussi-Pinhata, Marisa M., additional, Nanavati, Ruchi, additional, Nakwa, Firdose L., additional, Nangia, Sushma, additional, Nardone, Alessandra, additional, Nyaoke, Borna, additional, Obiero, Christina W, additional, Ping, Wang, additional, Preedisripipat, Kanchana, additional, Qazi, Shamim, additional, Qi, Lifeng, additional, Riddell, Amy, additional, Romani, Lorenza, additional, Roysuwan, Praewpan, additional, Saggers, Robin, additional, Saha, Samir, additional, Sarafidis, Kosmas, additional, Tusibira, Valerie, additional, Velaphi, Sithembiso, additional, Vilken, Tuba, additional, Wang, Xiaojiao, additional, Wang, Yajuan, additional, Yang, Yonghong, additional, Ellis, Sally, additional, Bielicki, Julia, additional, Walker, A Sarah, additional, Heath, Paul T., additional, and Sharland, Mike, additional

Published
2022
Full Text
View/download PDF

14. Patterns of antibiotic use, pathogens and clinical outcomes in hospitalised neonates and young infants with sepsis in the NeoOBS global neonatal sepsis observational cohort study

Author

Russell, Neal, primary, Stöhr, Wolfgang, additional, Plakkal, Nishad, additional, Cook, Aislinn, additional, Berkley, James A, additional, Adhisivam, Bethou, additional, Agarwal, Ramesh, additional, Balasegaram, Manica, additional, Ballot, Daynia, additional, Bekker, Adrie, additional, Berezin, Eitan Naaman, additional, Bilardi, Davide, additional, Boonkasidecha, Suppawat, additional, Carvalheiro, Cristina G., additional, Chaurasia, Suman, additional, Chiurchiu, Sara, additional, Cousens, Simon, additional, Cressey, Tim R., additional, Dien, Tran Minh, additional, Ding, Yijun, additional, Dramowski, Angela, additional, DS, Madhusudhan, additional, Dudeja, Ajay, additional, Feng, Jinxing, additional, Glupczynski, Youri, additional, Goossens, Herman, additional, Huertas, Tatiana Munera, additional, Islam, Mohammad Shahidul, additional, Jarovsky, Daniel, additional, Khavessian, Nathalie, additional, Khorana, Meera, additional, Kostyanev, Tomislav, additional, Larsson, Mattias, additional, Luca, Maia De, additional, Malhotra-Kumar, Surbhi, additional, Mussi-Pinhata, Marisa M., additional, Nanavati, Ruchi, additional, Nangia, Sushma, additional, Nankunda, Jolly, additional, Nardone, Alessandra, additional, Nyaoke, Borna, additional, Obiero, Christina W, additional, Owor, Maxensia, additional, Ping, Wang, additional, Preedisripipat, Kanchana, additional, Qazi, Shamim, additional, Ramdin, Tanusha, additional, Riddell, Amy, additional, Roilides, Emmanuel, additional, Saha, Samir K, additional, Sarafidis, Kosmas, additional, Thomas, Reenu, additional, Velaphi, Sithembiso, additional, Vilken, Tuba, additional, Wang, Yajuan, additional, Yang, Yonghong, additional, Zunjie, Liu, additional, Ellis, Sally, additional, Bielicki, Julia, additional, Walker, A Sarah, additional, Heath, Paul T., additional, and Sharland, Mike, additional

Published
2022
Full Text
View/download PDF

17. Development of tibia & fibula bone deficits in children with neurofibromatosis type I – A longitudinal case-control comparison

Author

Ireland, Alex, Riddell, Amy, Prentice, Ann, Eelloo, Judith, Mughal, M Zulf, Ward, Kate A, Ireland, Alex, Riddell, Amy, Prentice, Ann, Eelloo, Judith, Mughal, M Zulf, and Ward, Kate A

Abstract

Neurofibromatosis type 1 (NF1) is associated with lower bone mass and increased risk of fracture. Children with NF1 display faltering growth from mid-childhood. However, to date tibia bone development in children with NF1 across childhood and the role of body size have not been explored. Therefore, we recruited 24 children with NF1 (12 girls, mean age 8.2 ± 1.1y) and 104 children without NF1 (52 girls, mean age 11 ± 1.7y). Tibia and fibula bone characteristics were assessed at 4% and 38% distal-proximal tibia length in all children at baseline using peripheral quantitative computed tomography (pQCT). Longitudinal scans were obtained in 21 children with NF1 (12 girls) over 3.4 ± 0.3y and 71 children without NF1 (34 girls) over 1.1 ± 0.1y, such that at follow-up mean age of both groups (NF1 10.9 ± 1.3y, controls 11.4 ± 1.4y) were similar. Effects of group (NF1/control) on bone outcomes as well as group-by-age interactions, indicating differences in rate of change in bone outcome bone outcomes were assessed via linear mixed effects models with adjustment for sex, age, pubertal status and in additional models with adjustment for height and weight Z-scores. Group (NF1/control)-by-age interactions indicated a slower rate of tibia and fibula bone mass accrual in children with NF1 at all measured sites. These associations were attenuated by 25–50% by adjustment for height and weight Z-scores. At the 4% site, deficits in bone mass at older ages were related to slower trabecular BMD accrual. At the 38% site, group-by-age interactions suggested that bone mass deficits resulted from poorer accrual of cortical CSA and to a lesser extent cortical BMD. Lower limb bone mass deficits evident in children with NF1 appear to be progressive and emerge in mid-childhood. In part, they are related to development of a similar pattern of deficits in longitudinal growth and body weight in NF1. Interventions promoting muscle development or physical activity may be partially effective in attenu

Published
2021

18. Clinical Presentation and 28-Day Mortality in Hospitalized Neonates and Young Infants with Clinical Sepsis: The Global NeoOBS Observational Cohort

Author

Russell, Neal, primary, Stöhr, Wolfgang, additional, Plakkal, Nishad, additional, Cook, Aislinn, additional, Berkley, James A., additional, Adhisivam, Bethou, additional, Agarwal, Ramesh, additional, Balasegaram, Manica, additional, Ballot, Daynia, additional, Bekker, Adrie, additional, Berezin, Eitan Naaman, additional, Bilardi, Davide, additional, Boonkasidecha, Suppawat, additional, Carvalheiro, Cristina G., additional, Chaurasia, Suman, additional, Chiurchiu, Sara, additional, Cousens, Simon, additional, Cressey, Tim R., additional, Dien, Trah Minh, additional, Ding, Yijun, additional, Dramowski, Angela, additional, DS, Madhusudhan, additional, Dudeja, Ajay, additional, Feng, Jinxing, additional, Glupczynski, Youri, additional, Goossens, Herman, additional, Islam, Mohammad Shahidul, additional, Jarovsky, Daniel, additional, Khavessian, Nathalie, additional, Khorona, Meera, additional, Kostyanev, Tomislav, additional, Larsson, Matthias, additional, Luca, Maia De, additional, Malhotra-Kumar, Surbhi, additional, Mussi-Pinhata, Marisa M., additional, Nanavati, Ruchi, additional, Nangia, Sushma, additional, Nankunda, Jolly, additional, Nyaoke, Borna, additional, Obiero, Christina W., additional, Owor, Maxensia, additional, Ping, Wang, additional, Preedisripipat, Kanchana, additional, Qazi, Shamim, additional, Ramdin, Tanusha, additional, Riddell, Amy, additional, Roilides, Emmanuel, additional, Saha, Samir, additional, Sarafidis, Kosmas, additional, Thomas, Reenu, additional, Velaphi, Sithembiso Christopher, additional, Vilken, Tuba, additional, Wang, Yajuan, additional, Yang, Yonghong, additional, Zunjie, Liu, additional, Ellis, Sally, additional, Bielicki, Julia, additional, Walker, Sarah, additional, Heath, Paul T., additional, and Sharland, Mike, additional

Published
2021
Full Text
View/download PDF

19. Analysis from the NeoOBS Global Neonatal Sepsis Prospective Observational Cohort Study Across 19 Hospitals in 11 Countries; Clinical Presentation, Treatment, Mortality Outcomes and Development of the NeoSEP Sepsis Severity Score

Author

Russell, Neal, primary, Stöhr, Wolfgang, additional, Plakkal, Nishad, additional, Cook, Aislinn, additional, Berkley, James A., additional, Adhisivam, Bethou, additional, Agarwal, Ramesh, additional, Balasegaram, Manica, additional, Ballot, Daynia, additional, Bekker, Adrie, additional, Berezin, Eitan Naaman, additional, Bilardi, Davide, additional, Boonkasidecha, Suppawat, additional, Carvalheiro, Cristina G., additional, Chaurasia, Suman, additional, Chiurchiu, Sara, additional, Cousens, Simon, additional, Cressey, Tim R., additional, Dien, Trah Minh, additional, Ding, Yijun, additional, Dramowski, Angela, additional, Ds, Madhusudhan, additional, Dudeja, Ajay, additional, Feng, Jinxing, additional, Glupczynski, Youri, additional, Goossens, Herman, additional, Islam, Mohammad Shahidul, additional, Jarovsky, Daniel, additional, Khavessian, Nathalie, additional, Khorona, Meera, additional, Kostyanev, Tomislav, additional, Larsson, Matthias, additional, Luca, Maia De, additional, Malhotra-Kumar, Surbhi, additional, Mussi-Pinhata, Marisa M., additional, Nanavati, Ruchi, additional, Nangia, Sushma, additional, Nankunda, Jolly, additional, Nyaoke, Borna, additional, Obiero, Christina W., additional, Owor, Maxensia, additional, Ping, Wang, additional, Preedisripipat, Kanchana, additional, Qazi, Shamim, additional, Ramdin, Tanusha, additional, Riddell, Amy, additional, Roilides, Emmanuel, additional, Saha, Samir, additional, Sarafidis, Kosmas, additional, Thomas, Reenu, additional, Velaphi, Sithembiso Christopher, additional, Vilken, Tuba, additional, Wang, Yajuan, additional, Yang, Yonghong, additional, Zunjie, Liu, additional, Ellis, Sally, additional, Bielicki, Julia, additional, Walker, Sarah, additional, Heath, Paul T., additional, and Sharland, Mike, additional

Published
2021
Full Text
View/download PDF

20. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Author

Folegatti, Pedro M, primary, Ewer, Katie J, additional, Aley, Parvinder K, additional, Angus, Brian, additional, Becker, Stephan, additional, Belij-Rammerstorfer, Sandra, additional, Bellamy, Duncan, additional, Bibi, Sagida, additional, Bittaye, Mustapha, additional, Clutterbuck, Elizabeth A, additional, Dold, Christina, additional, Faust, Saul N, additional, Finn, Adam, additional, Flaxman, Amy L, additional, Hallis, Bassam, additional, Heath, Paul, additional, Jenkin, Daniel, additional, Lazarus, Rajeka, additional, Makinson, Rebecca, additional, Minassian, Angela M, additional, Pollock, Katrina M, additional, Ramasamy, Maheshi, additional, Robinson, Hannah, additional, Snape, Matthew, additional, Tarrant, Richard, additional, Voysey, Merryn, additional, Green, Catherine, additional, Douglas, Alexander D, additional, Hill, Adrian V S, additional, Lambe, Teresa, additional, Gilbert, Sarah C, additional, Pollard, Andrew J, additional, Aboagye, Jeremy, additional, Adams, Kelly, additional, Ali, Aabidah, additional, Allen, Elizabeth, additional, Allison, Jennifer L., additional, Anslow, Rachel, additional, Arbe-Barnes, Edward H., additional, Babbage, Gavin, additional, Baillie, Kenneth, additional, Baker, Megan, additional, Baker, Natalie, additional, Baker, Philip, additional, Baleanu, Ioana, additional, Ballaminut, Juliana, additional, Barnes, Eleanor, additional, Barrett, Jordan, additional, Bates, Louise, additional, Batten, Alexander, additional, Beadon, Kirsten, additional, Beckley, Rebecca, additional, Berrie, Eleanor, additional, Berry, Lisa, additional, Beveridge, Amy, additional, Bewley, Kevin R., additional, Bijker, Else Margreet, additional, Bingham, Tracey, additional, Blackwell, Luke, additional, Blundell, Caitlin L., additional, Bolam, Emma, additional, Boland, Elena, additional, Borthwick, Nicola, additional, Bower, Thomas, additional, Boyd, Amy, additional, Brenner, Tanja, additional, Bright, Philip D., additional, Brown-O'Sullivan, Charlie, additional, Brunt, Emily, additional, Burbage, Jamie, additional, Burge, Sharon, additional, Buttigieg, Karen R., additional, Byard, Nicholas, additional, Cabera Puig, Ingrid, additional, Calvert, Anna, additional, Camara, Susana, additional, Cao, Michelangelo, additional, Cappuccini, Federica, additional, Carr, Melanie, additional, Carroll, Miles W., additional, Carter, Victoria, additional, Cathie, Katrina, additional, Challis, Ruth J., additional, Charlton, Sue, additional, Chelysheva, Irina, additional, Cho, Jee-Sun, additional, Cicconi, Paola, additional, Cifuentes, Liliana, additional, Clark, Helen, additional, Clark, Elizabeth, additional, Cole, Tom, additional, Colin-Jones, Rachel, additional, Conlon, Christopher P., additional, Cook, Aislinn, additional, Coombes, Naomi S., additional, Cooper, Rachel, additional, Cosgrove, Catherine A., additional, Coy, Karen, additional, Crocker, Wendy E.M., additional, Cunningham, Christina J., additional, Damratoski, Brad E., additional, Dando, Lynne, additional, Datoo, Mehreen S., additional, Davies, Hannah, additional, De Graaf, Hans, additional, Demissie, Tesfaye, additional, Di Maso, Claudio, additional, Dietrich, Isabelle, additional, Dong, Tao, additional, Donnellan, Francesca R., additional, Douglas, Naomi, additional, Downing, Charlotte, additional, Drake, Jonathan, additional, Drake-Brockman, Rachael, additional, Drury, Ruth Elizabeth, additional, Dunachie, Susanna Jane, additional, Edwards, Nick J., additional, Edwards, Frances D.L., additional, Edwards, Chris J., additional, Elias, Sean C., additional, Elmore, Michael J., additional, Emary, Katherine R.W., additional, English, Marcus Rex, additional, Fagerbrink, Susanne, additional, Felle, Sally, additional, Feng, Shuo, additional, Field, Samantha, additional, Fixmer, Carine, additional, Fletcher, Clare, additional, Ford, Karen J., additional, Fowler, Jamie, additional, Fox, Polly, additional, Francis, Emma, additional, Frater, John, additional, Furze, Julie, additional, Fuskova, Michelle, additional, Galiza, Eva, additional, Gbesemete, Diane, additional, Gilbride, Ciaran, additional, Godwin, Kerry, additional, Gorini, Giacomo, additional, Goulston, Lyndsey, additional, Grabau, Caroline, additional, Gracie, Lara, additional, Gray, Zoe, additional, Guthrie, Lucy Belle, additional, Hackett, Mark, additional, Halwe, Sandro, additional, Hamilton, Elizabeth, additional, Hamlyn, Joseph, additional, Hanumunthadu, Brama, additional, Harding, Irasha, additional, Harris, Stephanie A., additional, Harris, Andrew, additional, Harrison, Daisy, additional, Harrison, Clare, additional, Hart, Thomas C., additional, Haskell, Louise, additional, Hawkins, Sophia, additional, Head, Ian, additional, Henry, John Aaron, additional, Hill, Jennifer, additional, Hodgson, Susanne H.C., additional, Hou, Mimi M., additional, Howe, Elizabeth, additional, Howell, Nicola, additional, Hutlin, Cecilia, additional, Ikram, Sabina, additional, Isitt, Catherine, additional, Iveson, Poppy, additional, Jackson, Susan, additional, Jackson, Frederic, additional, James, Sir William, additional, Jenkins, Megan, additional, Jones, Elizabeth, additional, Jones, Kathryn, additional, Jones, Christine E., additional, Jones, Bryony, additional, Kailath, Reshma, additional, Karampatsas, Konstantinos, additional, Keen, Jade, additional, Kelly, Sarah, additional, Kelly, Dearbhla, additional, Kerr, David, additional, Kerridge, Simon, additional, Khan, Liaquat, additional, Khan, Uzma, additional, Killen, Annabel, additional, Kinch, Jasmin, additional, King, Thomas B., additional, King, Lloyd, additional, King, Jade, additional, Kingham-Page, Lucy, additional, Klenerman, Paul, additional, Knapper, Francesca, additional, Knight, Julian C., additional, Knott, Daniel, additional, Koleva, Stanislava, additional, Kupke, Alexandra, additional, Larkworthy, Colin W., additional, Larwood, Jessica P.J., additional, Laskey, Anna, additional, Lawrie, Alison M., additional, Lee, Arlene, additional, Ngan Lee, Kim Yee, additional, Lees, Emily A, additional, Legge, Helen, additional, Lelliott, Alice, additional, Lemm, Nana-Marie, additional, Lias, Amelia M., additional, Linder, Aline, additional, Lipworth, Samuel, additional, Liu, Xinxue, additional, Liu, Shuchang, additional, Lopez Ramon, Raquel, additional, Lwin, May, additional, Mabesa, Francesca, additional, Madhavan, Meera, additional, Mallett, Garry, additional, Mansatta, Kushal, additional, Marcal, Ines, additional, Marinou, Spyridoula, additional, Marlow, Emma, additional, Marshall, Julia L., additional, Martin, Jane, additional, McEwan, Joanne, additional, McInroy, Lorna, additional, Meddaugh, Gretchen, additional, Mentzer, Alexander J., additional, Mirtorabi, Neginsadat, additional, Moore, Maria, additional, Moran, Edward, additional, Morey, Ella, additional, Morgan, Victoria, additional, Morris, Susan Jane, additional, Morrison, Hazel, additional, Morshead, Gertraud, additional, Morter, Richard, additional, Mujadidi, Yama F., additional, Muller, Jilly, additional, Munera-Huertas, Tatiana, additional, Munro, Claire, additional, Munro, Alasdair, additional, Murphy, Sarah, additional, Munster, Vincent J., additional, Mweu, Philomena, additional, Noé, Andrés, additional, Nugent, Fay L., additional, Nuthall, Elizabeth, additional, O'Brien, Katie, additional, O'Connor, Daniel, additional, Oguti, Blanché, additional, Oliver, Jennifer L., additional, Oliveira, Catarina, additional, O'Reilly, Peter John, additional, Osborn, Mairead, additional, Osborne, Piper, additional, Owen, Cathy, additional, Owens, Daniel, additional, Owino, Nelly, additional, Pacurar, Mihaela, additional, Parker, Kaye, additional, Parracho, Helena, additional, Patrick-Smith, Maia, additional, Payne, Victoria, additional, Pearce, Jennifer, additional, Peng, Yanchun, additional, Peralta Alvarez, Marco Polo, additional, Perring, James, additional, Pfafferott, Katja, additional, Pipini, Dimitra, additional, Plested, Emma, additional, Pluess-Hall, Helen, additional, Pollock, Katrina, additional, Poulton, Ian, additional, Presland, Laura, additional, Provstgaard-Morys, Samuel, additional, Pulido, David, additional, Radia, Kajal, additional, Ramos Lopez, Fernando, additional, Rand, Jade, additional, Ratcliffe, Helen, additional, Rawlinson, Thomas, additional, Rhead, Sarah, additional, Riddell, Amy, additional, Ritchie, Adam John, additional, Roberts, Hannah, additional, Robson, Joanna, additional, Roche, Sophie, additional, Rohde, Cornelius, additional, Rollier, Christine S., additional, Romani, Rossana, additional, Rudiansyah, Indra, additional, Saich, Stephen, additional, Sajjad, Sara, additional, Salvador, Stephannie, additional, Sanchez Riera, Lidia, additional, Sanders, Helen, additional, Sanders, Katherine, additional, Sapaun, Shari, additional, Sayce, Chloe, additional, Schofield, Ella, additional, Screaton, Gavin, additional, Selby, Beatrice, additional, Semple, Calum, additional, Sharpe, Hannah R., additional, Shaik, Imam, additional, Shea, Adam, additional, Shelton, Holly, additional, Silk, Sarah, additional, Silva-Reyes, Laura, additional, Skelly, Donal T., additional, Smee, Heather, additional, Smith, Catherine C., additional, Smith, David J., additional, Song, Rinn, additional, Spencer, Alexandra J., additional, Stafford, Elizabeth, additional, Steele, Amy, additional, Stefanova, Elena, additional, Stockdale, Lisa, additional, Szigeti, Anna, additional, Tahiri-Alaoui, Abdessamad, additional, Tait, Moira, additional, Talbot, Helen, additional, Tanner, Rachel, additional, Taylor, Iona Jennifer, additional, Taylor, Victoria, additional, Te Water Naude, Rebecca, additional, Thakur, Nazia, additional, Themistocleous, Yrene, additional, Themistocleous, Andreas, additional, Thomas, Merin, additional, Thomas, Tonia M., additional, Thompson, Amber, additional, Thomson-Hill, Samantha, additional, Tomlins, Jennifer, additional, Tonks, Susan, additional, Towner, James, additional, Tran, Nguyen, additional, Tree, Julia A., additional, Truby, Adam, additional, Turkentine, Kate, additional, Turner, Cheryl, additional, Turner, Nicola, additional, Turner, Sally, additional, Tuthill, Toby, additional, Ulaszewska, Marta, additional, Varughese, Rachel, additional, Van Doremalen, Neeltje, additional, Veighey, Kristin, additional, Verheul, Marije K., additional, Vichos, Iason, additional, Vitale, Elia, additional, Walker, Laura, additional, Watson, Marion E.E., additional, Welham, Benjamin, additional, Wheat, Julie, additional, White, Caroline, additional, White, Rachel, additional, Worth, Andrew T., additional, Wright, Danny, additional, Wright, Suzie, additional, Yao, Xin Li, additional, and Yau, Yasmine, additional

Published
2020
Full Text
View/download PDF

23. The muscle-bone in children and adolescents with and without cystic fibrosis

Author

Riddell, Amy

Subjects
cystic fibrosis, DXA, HR-pQCT, children, growth, imagining, Muscle, adolescents, Bone, muscle-bone unit, pQCT
Abstract

Puberty is a crucial period for rapid changes in bone mineral, size, geometry, and microarchitecture. The mechanostat theory postulates that increased mechanical loading will affect bone phenotype and strength during development and in later life. Individuals with cystic fibrosis(CF) have an increased risk of developing osteoporosis and fragility fractures in young adulthood, which may be caused by poor growth. The aim was to investigate whether sex and disease status modified the relationship between: 1) puberty and bone, and 2) muscle and bone. This would contribute to the understanding of how sex(malesvs.females) and disease group(CFvs.controls) alters the relationship between bone and muscle in children and adolescents as they transition through puberty and who, on a population level, differ in the prevalence of osteoporosis and risk of fracture in later life. This observational study used novel imaging and muscle assessment techniques to measure bone and muscle parameters in White Caucasian children and adolescents, aged 8 to 16 years, living in the UK, with children with CF(n=65) and controls(n=151). Anthropometry and pubertal status were assessed. Dual energy x-ray absorptiometry, peripheral quantitative computed tomography(pQCT), high-resolution pQCT, and jumping mechanography were used to measure bone and muscle outcomes. ANCOVA with Scheffé post hoc and multiple linear regression tests were performed. Data were adjusted according to the research aims and included covariates; sex, disease group, pubertal stage, age, quadratic age, height, weight, maximum force(Fmax), and maximum power(Pmax). Data are presented as beta-coefficient(%) and p-value, with the significance level set to p, MRC

Published
2017
Full Text
View/download PDF

24. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY):A multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

Author

Sivaprasad, Sobha, Prevost, A. Toby, Vasconcelos, Joana C., Riddell, Amy, Murphy, Caroline, Kelly, Joanna, Bainbridge, James, Tudor-Edwards, Rhiannon, Hopkins, David, and Hykin, Philip

Abstract

Background: Proliferative diabetic retinopathy is the most common cause of severe sight impairment in people with diabetes. Proliferative diabetic retinopathy has been managed by panretinal laser photocoagulation (PRP) for the past 40 years. We report the 1 year safety and efficacy of intravitreal aflibercept. Methods: In this phase 2b, single-blind, non-inferiority trial (CLARITY), adults (aged ≥18 years) with type 1 or 2 diabetes and previously untreated or post-laser treated active proliferative diabetic retinopathy were recruited from 22 UK ophthalmic centres. Patients were randomly assigned (1:1) to repeated intravitreal aflibercept (2 mg/0·05 mL at baseline, 4 weeks, and 8 weeks, and from week 12 patients were reviewed every 4 weeks and aflibercept injections were given as needed) or PRP standard care (single spot or mutlispot laser at baseline, fractionated fortnightly thereafter, and from week 12 patients were assessed every 8 weeks and treated with PRP as needed) for 52 weeks. Randomisation was by minimisation with a web-based computer generated system. Primary outcome assessors were masked optometrists. The treating ophthalmologists and participants were not masked. The primary outcome was defined as a change in best-corrected visual acuity at 52 weeks with a linear mixed-effect model that estimated adjusted treatment effects at both 12 weeks and 52 weeks, having excluded fluctuations in best corrected visual acuity owing to vitreous haemorrhage. This modified intention-to-treat analysis was reapplied to the per protocol participants. The non-inferiority margin was prespecified as -5 Early Treatment Diabetic Retinopathy Study letters. Safety was assessed in all participants. This trial is registered with ISRCTN registry, number 32207582. Findings: We recruited 232 participants (116 per group) between Aug 22, 2014 and Nov 30, 2015. 221 participants (112 in aflibercept group, 109 in PRP group) contributed to the modified intention-to-treat model, and 210 participants (104 in aflibercept group and 106 in PRP group) within per protocol. Aflibercept was non-inferior and superior to PRP in both the modified intention-to-treat population (mean best corrected visual acuity difference 3·9 letters [95% CI 2·3-5·6], pInterpretation: Patients with proliferative diabetic retinopathy who were treated with intravitreal aflibercept had an improved outcome at 1 year compared with those treated with PRP standard care. Funding: The Efficacy and Mechanism Evaluation Programme, a Medical Research Council and National Institute for Health Research partnership.

Published
2017

25. Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT

Author

Sivaprasad, Sobha, primary, Hykin, Philip, additional, Prevost, A Toby, additional, Vasconcelos, Joana, additional, Riddell, Amy, additional, Ramu, Jayashree, additional, Murphy, Caroline, additional, Kelly, Joanna, additional, Edwards, Rhiannon Tudor, additional, Yeo, Seow Tien, additional, Bainbridge, James, additional, Hopkins, David, additional, and White-Alao, Beverley, additional

Published
2018
Full Text
View/download PDF

28. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

Author

Sivaprasad, Sobha, primary, Prevost, A Toby, additional, Vasconcelos, Joana C, additional, Riddell, Amy, additional, Murphy, Caroline, additional, Kelly, Joanna, additional, Bainbridge, James, additional, Tudor-Edwards, Rhiannon, additional, Hopkins, David, additional, Hykin, Philip, additional, Bhatnagar, A, additional, Burton, B, additional, Chakravarthy, U, additional, Eleftheriadis, H, additional, Empeslidis, T, additional, Gale, R, additional, George, S, additional, Habib, M, additional, Kelly, S, additional, Lotery, A, additional, McKibbin, M, additional, Membrey, L, additional, Menon, G, additional, Mushtaq, B, additional, Nicholson, L, additional, Ramu, J, additional, Osoba, O, additional, Patel, J, additional, Prakash, P, additional, Purbrick, R, additional, Ross, A, additional, Stylianides, A, additional, Talks, J, additional, Harding, S, additional, Peto, T, additional, Yeo, S T, additional, Laidlaw, Alistair, additional, Amoaku, Winfried, additional, Hood, Gillian, additional, Hitman, Graham A, additional, Preece, Daniel, additional, Burns, Paul, additional, Walker, Sarah, additional, Mensah, Evelyn, additional, and Karia, Niral, additional

Published
2017
Full Text
View/download PDF

34. Intravitreal aflibercept for proliferative diabetic retinopathy –reply.

Author

Sivaprasad, Sobha, Prevost, A. Toby, Vasconcelos, Joana, Riddell, Amy, and Hykin, Philip

Subjects
*DIABETIC retinopathy, *LIGHT coagulation
Abstract

A review of the article related to the clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for visual acuity in patients with proliferative diabetic retinopathy by S. Sivaprasad, which appeared in the periodical "Lancet" in 2017, is presented.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results